Research and Markets: The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d00bca/the_future_of_cent) has announced the addition of the "The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" report to their offering.

“The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis”

GBI, the leading business intelligence provider has released its latest research, "The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" provides key data, information and analysis on the global CNS therapeutics market. The report provides market landscape, competitive landscape and market trends information on seven disease categories which include; Alzheimer's disease, Parkinson's disease, Schizophrenia and Bi-polar disorder, Major Depressive Disorder, Anxiety and Panic disorder, Attention Deficit Hyperactivity Disorder and Insomnia. The report also provides annualized market revenues data from 2000 to 2008, forecast until 2015 for all the mentioned disease sectors. The report covers seven geographies which include; the US, the UK, Germany, France, Spain and Italy and Japan. This report provides comprehensive information on the key trends effecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape in terms of mergers and acquisitions, pipeline products and technology offerings. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by a team of experts.

CNS Therapeutics Market is Forecast To Show Slow Growth Till 2015

The global CNS therapeutics market was valued at $99 billion in 2008 and will be driven by the increasing ageing population and the steady increase in incidence rates of CNS complications. This market is expected to grow to $121 billion with a CAGR of 2.8% by year 2015. The authors examined the CNS markets in US, EU5 (includes UK, France, Germany, Italy and Spain) and Japan. Of all the covered countries, the market size in US was the largest as compared to other regions. The market is also growing the fastest in US as compared to other regions. This is explained primarily by both the price differentials that are observed in US at a higher rate compared to other regions as well as the higher volume of diseased and pharmacotherapy treated population.

CNS Therapeutics Market, Global, Key Geographical Trends, 2008

Global CNS Therapeutics Market: The Entry of Generic Substitutes at Substantially Lower Prices is Forecast to Be a Major Threat for Primary Drug Manufacturers

Globally, the US remains the largest sector in terms of revenues. The US CNS therapeutics market in 2008 represented 52 % share over the total CNS therapeutics market. Countries like China and India have been identified as potential emerging markets for major pharmaceutical companies to invest in. A major factor posing a threat to this market is the expiration of patents for many block buster drugs in the next three years. The entry of generic substitutes at substantially lower prices could be very debilitating for major manufacturers. Markets like Japan and other south Asian countries have shown increasing acceptance of generics under their reimbursement protocols. European countries face high risk from parallel importing coupled with effective bans on the reimbursements for certain CNS diseases.

Scope

The scope of this report includes:

Annualized market data for the CNS diseases therapeutics market from 2000 to 2008, forecast forward to 2015
Analysis of the leading therapeutic segments including Alzheimer's disease, Parkinson's disease, Schizophrenia and Bipolar Disorder, Epilepsy, Major depressive disorder (MDD), anxiety and panic disorder, Attention Deficit Hyperactivity Disorder (ADHD) and Insomnia.
Analysis of the CNS diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
Market characterization of the CNS diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
Key drivers and barriers that have a significant impact on the market
Coverage of pipeline molecules in various phases of drug development
Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Lundbeck A/S, AstraZeneca, Merck & Co, Pfizer Inc, UCB S.A., Bristol-Myers Squibb and Eli Lilly
Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global CNS diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align product portfolio to the markets with high growth potential
Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
Develop key strategic initiatives by understanding key focus areas of leading companies
Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Key Topics Covered:

Global CNS Therapeutics Market : Introduction